Deciphera Pharmaceuticals Inc (DCPH.OQ)
DCPH.OQ on NASDAQ Stock Exchange Global Select Market
39.55USD
22 Jun 2018
39.55USD
22 Jun 2018
Change (% chg)
$-5.40 (-12.01%)
$-5.40 (-12.01%)
Prev Close
$44.95
$44.95
Open
$45.08
$45.08
Day's High
$45.08
$45.08
Day's Low
$36.57
$36.57
Volume
369,604
369,604
Avg. Vol
67,203
67,203
52-wk High
$45.61
$45.61
52-wk Low
$15.37
$15.37
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 0.00 | -0.657 |
| FY 2017 | Dec '17 | 0.00 | -0.649 |
| Sep '17 | 0.00 | -0.392 | |
| Jun '17 | 0.00 | -0.346 | |
| Mar '17 | 0.00 | -0.251 | |
| FY 2016 | Dec '16 | 0.00 | -0.279 |
| Sep '16 | 0.00 | -2.964 | |
| Jun '16 | 0.00 | -0.193 | |
| Mar '16 | 0.00 | -0.174 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 4 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Sep-18 | 4 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-18 | 5 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-19 | 5 | 15.00 | 75.00 | 0.00 | -- |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 5 | -0.69 | -0.65 | -0.76 | -- |
| Quarter Ending Sep-18 | 5 | -0.69 | -0.63 | -0.75 | -- |
| Year Ending Dec-18 | 5 | -2.74 | -2.59 | -2.93 | -- |
| Year Ending Dec-19 | 5 | -2.69 | -0.59 | -3.55 | -- |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 82.81 | 32.74 | |
| P/E High - Last 5 Yrs. | -- | 289.15 | 45.73 | |
| P/E Low - Last 5 Yrs. | -- | 90.24 | 24.23 | |
| Beta | -- | 0.91 | 0.88 | |
| Price to Sales (TTM) | -- | 109.18 | 5.71 | |
| Price to Book (MRQ) | -- | 13.44 | 5.37 | |
| Price to Tangible Book (MRQ) | 8.04 | 13.96 | 6.94 | |
| Price to Cash Flow (TTM) | -- | 70.39 | 23.32 | |
| % Owned Institutions | -- | 13.84 | 2.17 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.34 | 1.50 | |
| Dividend Yield - 5 Year Avg | -- | 0.25 | 1.51 | |
| Dividend 5 Year Growth Rate | -- | 1.64 | 5.32 | |
| Payout Ratio(TTM) | -- | 15.83 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 392.54 | 7.89 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 77.35 | 5.68 | |
| Sales - 5 Yr. Growth Rate | -- | 32.11 | 10.33 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -79.11 | 24.53 | 19.38 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -- | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 39.08 | 10.78 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 40.34 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.83 | 2.19 |
| Current Ratio (MRQ) | 11.53 | 5.26 | 2.98 |
| LT Debt to Equity (MRQ) | 1.59 | 24.54 | 12.19 |
| Total Debt to Equity (MRQ) | 1.80 | 26.17 | 16.46 |
| Interest Coverage (TTM) | -- | -97.42 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 40.81 | 54.46 | |
| Gross Margin - 5 Yr. Avg. | -- | 51.76 | 52.22 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -564.12 | 10.98 | |
| Operating Margin (TTM) | -- | -706.11 | 4.74 | |
| Operating Margin - 5 Yr. Avg. | -- | -585.15 | 6.41 | |
| Pre-Tax Margin (TTM) | -- | -681.03 | 5.58 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -588.45 | 6.83 | |
| Net Profit Margin (TTM) | -- | -682.46 | 1.88 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -591.46 | 3.10 | |
| Effective Tax Rate (TTM) | -- | 22.64 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.26 | 23.95 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | -- | 22,312,275 | 846,855,612 | |
| Net Income/Employee (TTM) | -- | 2,947,385 | 99,619,380 | |
| Receivable Turnover (TTM) | -- | 19.92 | 5.78 | |
| Inventory Turnover (TTM) | -- | 2.37 | 3.35 | |
| Asset Turnover (TTM) | -- | 0.39 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -- | -0.70 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | -- | -0.06 | 12.32 | |
| Return on Investment (TTM) | -- | 2.00 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | -- | 2.81 | 16.11 | |
| Return on Equity (TTM) | -- | 3.49 | 16.08 | |
| Return on Equity - 5 Yr. Avg. | -- | 4.33 | 17.41 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -30.90 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Deciphera Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -- | -- | -- | 53 |
| 13 Week | -- | -- | -- | 69 |
| 26 Week | -- | -- | -- | 77 |
| 52 Week | -- | -- | -- | 48 |
| YTD | -- | -- | -- | 59 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Deciphera Pharmaceuticals Reports Q1 Loss Per Share $0.66
- BRIEF-Deciphera Pharma Expects To Start Late-Stage Study In Patients With Gastric Tract Tumors In Second Half Of 2018
- BRIEF-Deciphera Pharmaceuticals Q4 Loss Per Share $0.62
- BRIEF-Deciphera Pharma Initiates Late Stage Study In Gastrointestinal Cancer Patients
Institutional Holders
| % Shares Owned: | 42.39% |
| # of Holders: | 76 |
| Total Shares Held: | 15,641,241 |
| 3 Mo. Net Change: | -139,890 |
| # New Positions: | 15 |
| # Closed Positions: | 15 |
| # Increased Positions: | 37 |
| # Reduced Positions: | 39 |
| # Net Buyers: | -2 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.